Avita Medical will host an investor webinar briefing on August 12, 2026, providing
shareholders and prospective investors with an update on its financial and business
performance.

The Nasdaq- and ASX-listed therapeutic acute wound care company said the presentation
will be led by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief
Financial Officer.

The webinar is scheduled for 4 p.m. Pacific Time on August 12, corresponding to 9 a.m.
Australian Eastern Standard Time on August 13.

Q&A to Follow Presentation

The briefing will focus on Avita Medical’s financial and operational results discussed during
its recently held second-quarter 2026 earnings webcast. The session will conclude with a
question-and-answer segment, giving participants an opportunity to engage with company
leadership.

Shareholders and prospective investors can submit questions through the webinar registration
page ahead of the event.

A recording of the presentation will also be made available on the company’s investor
relations website following the briefing.

RECELL Leads Wound Care Portfolio

Avita Medical develops therapeutic solutions designed to improve wound healing and
accelerate patient recovery. Its primary technology, RECELL, is approved by the U.S. Food
and Drug Administration for treating thermal burn and trauma wounds.

The platform uses a patient’s own skin to create Spray-On Skin, an approach designed to
support wound treatment at the point of care while potentially improving clinical outcomes.
In the United States, Avita Medical also has exclusive rights to market, sell and distribute
Cohealyx, its branded collagen-based dermal matrix. The company additionally holds
exclusive rights to manufacture, market, sell and distribute PermeaDerm, a biosynthetic
wound matrix.

Global Regulatory Presence

Avita Medical’s products have secured regulatory approvals and certifications across several
international markets. RECELL is approved for various applications involving skin healing,
including thermal burns and trauma wounds.
RECELL and RECELL GO are CE-marked in Europe, while RECELL holds TGA
certification in Australia and is listed with Medsafe in New Zealand. The technology is also
approved by Japan’s PMDA.

The upcoming investor briefing will offer stakeholders an opportunity to assess the
company’s latest financial results, business developments and outlook directly from its senior
management team.

Also Read :- Total Flow Medical Secures FDA Clearance for Cardiopulmonary Bypass Cannula